Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation  by Leiser, Dominic et al.
FEBS Letters 588 (2014) 653–658journal homepage: www.FEBSLetters .orgTargeting of the MET receptor tyrosine kinase by small molecule
inhibitors leads to MET accumulation by impairing the receptor
downregulation0014-5793/$36.00  2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.febslet.2013.12.025
Abbreviations: RTK, receptor tyrosine kinase; TKI, tyrosine kinase inhibitor; HGF,
hepatocyte growth factor; wt, wild type; TKB, tyrosine kinase binding
⇑ Corresponding author at: Department of Radiation Oncology, Inselspital, Bern
University Hospital, and University of Bern, Switzerland.
E-mail address: michaela.medova@dkf.unibe.ch (M. Medová).Dominic Leiser, Benoît Pochon, Wieslawa Blank-Liss, Paola Francica, Astrid A. Glück, Daniel M. Aebersold,
Yitzhak Zimmer, Michaela Medová ⇑
Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, 3010 Bern, Switzerland
Department of Clinical Research, University of Bern, 3010 Bern, Switzerland
a r t i c l e i n f o a b s t r a c tArticle history:
Received 25 August 2013
Revised 25 November 2013
Accepted 17 December 2013
Available online 17 January 2014
Edited by Veli-Pekka Lehto
Keywords:
MET
Small molecule tyrosine kinase inhibitor
Receptor downregulation
CBL
Receptor ubiquitination
MET Tyr1003The MET receptor tyrosine kinase is deregulated primarily via overexpression or point mutations in
various human cancers and different strategies for MET inhibition are currently evaluated in clinical
trials. We observed by Western blot analysis and by Flow cytometry that MET inhibition by different
MET small molecule inhibitors surprisingly increases in a dose-dependent manner total MET levels
in treated cells. Mechanistically, this inhibition-related MET accumulation was associated with
reduced Tyr1003 phosphorylation and MET physical association with the CBL ubiquitin ligase with
concomitant decrease in MET ubiquitination. These data may suggest careful consideration for
design of anti-MET clinical protocols.
Structured summary of protein interactions:
Cbl physically interacts withMet by anti bait coimmunoprecipitation (1, 2)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction signaling molecules. Consequently, crucial biologic activities as cellDeregulated oncogenic activity of the receptor tyrosine kinase
(RTK) MET for hepatocyte growth factor (HGF) is abundantly found
in numerous types of human malignancies and is ﬁrmly correlated
with diverse aspects of cancer pathogenesis and progression. In
addition to MET receptor overexpression that is considered the
major mode of ligand-independent deregulation of MET function,
tyrosine kinase-activating mutations of MET have been described
in papillary renal carcinomas as well as other human tumors
[1–3]. The biologic signiﬁcance of these mutations could be in
the near future associated with resistance to MET targeted therapy
similar to the accumulating experience with BCR-ABL, KIT and
EGFR inhibitors.
Under normal conditions and following activation of the MET
kinase, tyrosine residues at the receptor C-terminus are phosphor-
ylated, creating docking sites for various MET downstreamproliferation, motility, invasion as well as receptor downregulation
are tightly regulated. In that respect, phosphorylation leads to
recruitment of the Grb2 adaptor protein, which recruits the E3
ubiquitin-protein ligase CBL [4–6]. If, in addition, tyrosine at posi-
tion 1003 in the MET juxtamembrane domain is phosphorylated, a
direct recruitment and activation of CBL through the CBL tyrosine
kinase binding (TKB) domain is accomplished [5]. Upon binding
and activation of CBL, MET is ubiquitinated [5]. This posttransla-
tional modiﬁcation is required for efﬁcient recognition of MET dur-
ing trafﬁcking and leads to receptor degradation in the lysosome
[7,8].
In cancer cells, there are different ways by which the receptor
downregulation may be impaired. One example in this context is
the TPR–MET fusion protein generated by carcinogen-induced
chromosomal rearrangement that fuses a protein dimerization do-
main TPR to MET kinase domain, resulting in the deletion of the
juxtamembrane Tyr1003 TKB site ofMET. The lack of the juxtamem-
brane region containing Tyr1003 hinders the subsequent recruit-
ment of CBL via its TKB domain and MET ubiquitination, and as a
result, the receptor fails to degrade in the lysosome [9]. Aside of
TPR–MET, naturally occurring MET variants that lack the CBL
binding site have been identiﬁed in cancer tissues, showing the
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anism counteracting tumorigenesis. For example, in both non-small
cell lung cancer cell lines and adenocarcinoma lung tumors, alterna-
tively spliced mutants of MET that result in the excision of exon 14
containing the CBL TKB domain site (Tyr1003) have been identiﬁed
[10–12]. These MET variants show enhanced stability and pro-
longed signaling and oncogenic capacity [11]. In addition, in the gas-
tric cancer cell line Hs746T the ampliﬁedMET possesses a mutation
that results in the loss of exon 14 [13], pointing to the fact that the
loss of negative regulation by CBL may be selected also in cases of
MET ampliﬁcation.
Furthermore, in an experimental system in which the phos-
phorylation of Tyr1003 is abrogated by substitution of the CBL
binding site Tyr1003 with a phenylalanine residue, CBL binding
to MET is hampered, leading to a poorly ubiquitinated and stable
MET receptor with a subsequent transforming potential both
in vitro and in vivo [7].
Other observations in this respect were recently published by
Joffre et al. who have characterized MET endocytosis of the wild
type (wt) receptor and two activating MET mutants M1268T and
D1246N, stably expressed in NIH3T3 cells [14]. The total abun-
dance of the mutants was shown to be similar to that of the wt
receptor; however, there was substantial basal accumulation of
MET mutants in endosomal compartments. Analysis of MET traf-
ﬁcking within this study indicated not only that internalization
of the active mutant was enhanced compared with wt protein
but also that recycling of the M1268T mutant was more efﬁcient.
In these experiments especially the cell-surface abundance of
M1268T receptor could be even further increased by expression
of a dominant negative Rab11, which blocks the slow recycling
pathway [15].
Because MET is considered an important molecular target in
cancer therapy, various strategies to inhibit its activity have al-
ready proceeded to clinical trials. Among the most promising
MET-inhibitory approaches are small molecule tyrosine kinase
inhibitors (TKIs). In the present study we used two preclinical
MET small molecule inhibitors, SU11274 and PHA665752 as well
as two other MET inhibitors, the MET speciﬁc EMD1214063 and
the non-speciﬁc MET TKI PF02341066 (Crizotinib), that have al-
ready entered clinical evaluations [16,17].
Here we show that MET inhibition by different small molecule
inhibitors causes accumulation of the MET receptor on the cellular
membrane most likely due to the impairment of the receptor
downregulation. We propose that the phosphorylation inhibition
of Tyr1003 by the small molecule TKI and consequent reduced
CBL binding and ubiquitination of MET leads probably to a reduced
lysosomal degradation of MET.
2. Materials and methods
2.1. Cell lines
The human lung adenocarcinoma cell line H1993 with MET wt
overexpression was kindly provided by the lab of Dr. S. Giordano
(Torino, Italy) and was maintained in the RPMI medium (GIBCO,
Invitrogen Corp.) supplemented with 10% FCS (Sigma) and antibi-
otics-antimycotic (penicillin 100 U/ml, streptomycin sulfate
100 U/ml, amphotericin B as Fungizone 0.25 lg/ml; GIBCO). The
NIH3T3 mouse ﬁbroblast cell lines stably expressing activating
MET-mutated variants H1112L, M1268T, V1110I, V1238I, L1213V
or Y1248H were all obtained from Dr. L. Schmidt (NCI, Maryland,
USA) and were cultured in DMEM medium (GIBCO) supplemented
with 10% FCS, antibiotics-antimycotic and 0.5 mg/ml Geneticin/
G-418 sulfate (GIBCO).2.2. Drugs
The MET inhibitor SU11274 was obtained from SUGEN, Inc.
(South San Francisco, CA, USA), EMD1214063 (MSC2156119J) from
Merck-Serono (Darmstadt, Germany) and PHA665752 and
PF02341066 (kind gift from Dr. A. Rothschild (University of Bern,
Switzerland)) from Pﬁzer (La Jolla, CA). All MET inhibitors were dis-
solved in DMSO and working solutions were prepared freshly in
the corresponding media.
2.3. Western blotting, immuno- and co-immunoprecipitations
Following 16 h of treatment with MET inhibitor, cells were
lysed in a buffer containing 1% Triton X-100, 0.5% NP-40, 1 mM
EGTA, 1 mM EDTA, 150 mM NaCl, 10 mM Tris–HCl, 1 mM Na3VO4,
10 mM NaF, 1 mM ZnCl2, 50 lM Na2MoO4, and a protease inhibi-
tors cocktail (Roche; Basel, Switzerland) and cell extracts were
cleared by centrifugation. Total protein concentration was deter-
mined using the BioRad protein quantiﬁcation reagent (Bio-Rad
Laboratories, Inc.). Fifty to 100 lg of total proteins was resolved
by SDS–PAGE on 7% gels, transferred onto PVDF membranes and
followed by incubation with indicated antibodies. Detection of sec-
ondary antibodies conjugated to horseradish peroxidase was per-
formed using the ECL kit (Amersham Pharmacia Biotech, UK).
Where indicated, quantiﬁcation of ECL signals was performed
using Quantity One software (BioRad).
To detect MET–CBL interaction as well as MET ubiquitination
status, total protein lysates (0.5 mg) were incubated with 1 lg of
corresponding antibody (CBL or MET) and subsequently, lMACS
protein G Microbeads (Miltenyi Biotec, Germany) were added.
After calibration, columns were loaded with samples and washed
with high and low salt buffers. Beads were boiled with sample buf-
fer and the immunoprecipitated complexes were subsequently
analyzed by SDS–PAGE and probed for the presence of MET, CBL
or ubiquitin by speciﬁc antibodies.
For standardization of the Ubiquitin-IP, total MET levels were
measured by Western blotting, quantiﬁed using QuantityOne soft-
ware (BioRad) and samples were adjusted to have equal amount of
the MET protein.
To quantify the CBL–MET interaction, we measured the density
of the bands of the pull-down sample as well as of the total lysate
(this value was used for standardization) from 5 independent
experiments, calculated the relative values between the untreated
and treated samples, and used a paired t-test to obtain the P-value.
2.4. Antibodies
The rabbit polyclonal anti-phospho-MET (Tyr1234/1235) anti-
body was purchased from Cell Signaling Technology and the rabbit
polyclonal anti-phospho-MET (Tyr1003) from Biosource. The rab-
bit polyclonal anti-MET and anti-CBL antibodies were purchased
from Santa Cruz Biotechnology and rabbit anti-Actin antibody
was from Sigma (Fluka, Buchs, Switzerland). The mouse mono-
and polyubiquitinylated antibody was purchased from ENZO (Enzo
Life Sciences Inc, Farmingdale, USA). The rat afﬁnity puriﬁed anti-
mouse c-Met antibody and the APC Donkey F(ab0)2 Fragment anti
Rat IgG (H + L) Minimal reactivity to mouse IgG antibody was from
eBioscience (eBioscience, Inc. San Diego, USA).
2.5. Flow cytometry
Following 16 h of MET inhibitor treatment, cells were washed
with PBS and scraped from the culture plates. Unspeciﬁc binding
was blocked by 30% donkey serum (SIGMA) in PBS and cells were
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ary anti-rat antibody. Relative ﬂuorescence intensities were
measured with a BD LSRII (BD, Mountain View, CA). Data were ana-
lyzed using FlowJo™ software (Tree Star, Ashland, OR).
3. Results
3.1. MET inhibition by small molecule TKIs increases total cellular MET
protein levels
Small molecule TKIs against MET RTK are chemical compounds
designed to block MET activity by binding to the ATP-binding
pocket and subsequently to restrict various MET-dependent bio-
logical features (reviewed in [18–21]). As such, we and others have
shown that MET inhibition by small molecule TKIs affects MET
tyrosine kinase autophosphorylation (Tyr1234/1235 residues),
with consequent decreased cell proliferation, survival, anchorage-
independent growth and changes in cellular morphology [12,22–
25]. Here we show by Western blotting that the four various
MET small molecule inhibitors, SU11274, PHA665752,
EMD1214063, and PF02341066, efﬁciently inhibit MET autophos-
phorylation at kinase tyrosines 1234/1235 in ﬁve out of seven cell
lines that have been tested, but, concomitantly, increase in a dose-
dependent manner total MET levels (Fig. 1). We observe this phe-
nomenon, surprisingly not previously reported, both in cells over-
expressing the wt MET (human non-small cell lung cancer line
H1993) as well as in NIH3T3 cells expressing activating MET mu-
tated variants that overall respond to MET inhibition (MET
H1112L, M1268T, V1110I, and V1238I mutations). Contrary,
NIH3T3 MET L1213V and NIH3T3 MET Y1248H mutants, that have
been previously shown to be resistant to MET small molecule
inhibitors [22,23,26], do not respond to MET inhibition by decreaseMET wt
cell line
H1993            H1112L     M1268T 
pMET
cMET
β Actin
SU11274 (µM)      0   0.5   2            0   0.5   2       0    0.5   2
MET m
Sensitive
pMET
cMET
β Actin
PHA665752 (nM)    0  100  300            0  100  300   0  100  300
pMET
cMET
β Actin
EMD1214063 (nM)   0    10    25           0    10   25     0    10 25
pMET
cMET
β Actin
PF02341066 (nM)    0    50   100          0    50 100     0   50  100
Fig. 1. Receptor inhibition by small molecules reduces the status of phosphorylated ME
H1993 and NIH3T3 cells expressing drug-sensitive or drug-resistant MET mutants were t
levels and activation were analyzed by Western blotting. Experiments were performed
phosphorylation; bActin – loading control).in tyrosine autophosphorylation and also do not display the in-
crease in total MET protein upon treatment with any of the
currently used MET inhibitors (Fig. 1). These observations suggest
that efﬁcient inhibition of the MET receptor by small molecule
inhibitors is often correlated with moderate to considerable in-
creases of total MET cellular protein levels.
3.2. MET accumulation upon receptor inhibition occurs on the cell
membrane
In order to conﬁrm this observation by an independent method
and to determine whether the accumulation of the MET receptor
upon treatment with small molecules leads to increased expres-
sion of the receptor on the cell surface or it is rather a result of
its intracellular accumulation, we performed Flow cytometry
experiments. We compared, by using an antibody that recognizes
the extracellular portion of the receptor, the presence of the MET
protein in MET inhibitor-treated versus untreated cells. The results
suggest an accumulation of MET on the cell membrane in the case
of the drug-sensitive NIH3T3 MET M1268T mutant cells whereas
no change of MET protein levels on the surface of PHA665752-
resistant NIH3T3 MET Y1248H mutant cells can be observed
(Fig. 2).
3.3. Accumulation of the MET protein upon treatment with small
molecules interferes with proper MET receptor downregulation
We further postulated that the MET kinase inhibition-associ-
ated upregulation of MET levels could be correlated with a de-
creased downregulation of the protein. Concerning a potential
downregulation mechanism, it is currently well-established that
the CBL proto-oncogene serves as a negative regulator of MET     V1110I       V1238I        L1213V      Y1248H
      0    0.5   2       0    0.5   2       0     0.5   2      0 0.5   2 
utated variants in NIH 3T3 cells
 to METi Resistant to METi
     0  100  300 0  100  300 0  100  300    0  100  300
      0    10   25      0    10    25     0   10   25      0   10   25
    0    50  100     0    50  100     0   50   100      0   50   100 
T but leads to signiﬁcant increase in total MET levels. Human lung cancer cell line
reated with the indicated concentrations of MET inhibitors for 16 h and MET protein
in three repetitions, representative results are shown. (pMET – Tyr1234/1235 MET
Fig. 2. Treatment by the TKI PHA665752 leads to increased membrane MET levels. Membrane MET levels in NIH3T3 MET M1268T and MET Y1248H cells (untreated cells
versus cells treated by 100 or 300 nM of PHA665752 for 16 h) were determined by Flow cytometry. (A) Illustrative picture, membrane MET levels in NIH3T3 MET M1268T
cells untreated (red) and treated by 100 or 300 nM PHA665752 (light and dark blue, respectively). (B) Quantiﬁcation of the data obtained in three independent experiments.
(P-values (for difference in the mean of treatment group, ANOVA was applied), P < 0.05 was considered statistically signiﬁcant).
Fig. 3. The status of phospho-MET (Tyr1003) decreases following TKI PHA665752 treatment. Cells were treated with the indicated concentrations of PHA6675752 for 16 h
and MET protein levels and activation were analyzed by Western blotting. Experiments were performed in three independent repetitions, data shown are representative
results. (p – phosphorylation).
Fig. 4. TKI treatment leads to a decreased interaction of MET and CBL and subsequently reduces MET ubiquitination. (A) Cells were treated with PHA665752 (300 nM for 16 h
before lysis) and the interaction between MET and CBL was determined by co-immunoprecipitation. Experiments were performed in ﬁve independent repetitions and MET–
CBL interaction (Mean ± S.D.) was quantiﬁed as detailed in Materials and Methods. Blots shown are representative results. (B) Cells were treated with PHA665752 as in (A)
and MET ubiquitination was determined by immunoprecipitation of the lysates with anti-MET antibody and subsequently stained for ubiquitin. Immunoblotting with anti-
MET antibody was performed as an internal loading control. Data shown are representative results of at least three independent experiments.
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brane domain of the MET receptor is required for recruitment of
the CBL TKB domain [20,27,28]. We report here that the phosphor-
ylation of Tyr1003 is abolished upon anti-MET treatment by
PHA665752 or SU11274 in a similar fashion as the phosphorylation
of the tyrosines Tyr1234/1235 that constitute the MET autophos-
phorylation sites (Fig. 3 & Supplementary Fig. 1).
Further in this line, we show by co-immunoprecipitation exper-
iments that PHA665752 treatment impairs the coupling of CBL to
MET with a consequent and signiﬁcant (P = 0.0045) decrease in
MET–CBL association in NIH3T3 MET M1268T cells where MET
activity was pharmacologically abrogated as compared to un-
treated controls (Fig. 4A). Since the MET–CBL binding is an indis-
pensable step preceding MET ubiquitination, we next aimed to
measure the impact of MET inhibition on the level of ubiquitina-
tion of the receptor. To that end, the samples were standardized
to have equal total-MET amounts and ubiquitination was studied
by immunoprecipitation. As shown in Fig. 4B, the observed disrup-
tion of CBL–MET association was indeed translated into decreased
MET ubiquitination and hence could be the tentative reason for re-
duced MET receptor degradation through the lysosome, resulting
in receptor accumulation in total and on the cell membrane.
As expected, and since the phosphorylation of the CBL-binding
site, MET Tyr1003, in NIH3T3 MET Y1248H cells is not affected
by PHA665752 or SU11274 (Fig. 3 & Supplementary Fig. 1), there
are also no changes observed in the treated versus untreated cells
in terms of MET–CBL association (Fig. 4A) and receptor ubiquitina-
tion (Fig. 4B & Supplementary Fig. 2).
Taken together, these data suggest that the impairment of MET
downregulation by small molecule TKIs is restricted to MET onco-
genic forms that respond to the given inhibitor and does not seem
to display off-target activity on the non-responsive MET variants.
4. Discussion
Deregulation of the MET RTK is associated with the pathology of
numerous human malignancies and partially predicts tumor
aggressiveness as well as resistance to treatment strategies [29–
31]. Aberrant MET activity that is unleashed by various molecular
modes such as receptor overexpression, autocrine/paracrine mech-
anisms and activating point mutations, is considered as an impor-
tant clinical target with anti-MET/anti-HGF antibodies and MET
small molecules serving as the predominant targeting modalities
(reviewed in [20]). MET small molecule inhibitors act by interfer-
ence with the receptor autophosphorylation on Tyr1234/1235
and subsequently prevent the phosphorylation and activity of
MET-downstream signaling adaptors and effectors [20]. Among
these downstream signaling proteins, CBL leads to the downregu-
lation of the receptor by ubiquitination and successive degradation
in the lysosomes. The activation-dependent downregulation is
important in keeping a steady-state of the receptor, balancing be-
tween active and non-active MET modes. Here we demonstrate
that by inhibition of the receptor activation, also the MET activa-
tion-dependent downregulation might be hindered. As a conse-
quence, the receptor accumulates on the cell membrane, where it
potentially could be stimulated once the administration of the
inhibitor is paused.
Based on our data, we propose that anti-MET small molecules
inhibit the phosphorylation on CBL TKB binding site (Tyr1003), dis-
rupting the interaction between MET and CBL and thus restricting
ubiquitination of receptors that subsequently cannot be internal-
ized and degradated in the lysosomes. Proper RTKs downregulation
is a crucial step in regulating their activity and if not tightly con-
trolled, may display oncogenic potential. This can be convincingly
illustrated on the example of the TPR–MET fusion protein as de-scribed in a detailed way in the introduction. This oncoprotein is,
similarly to cellular systems used in the current study (e.g., MET
wt overexpression and MET activating mutations), constitutively
active but due to the Tyr1003 deletion fails to bind CBL and to
undergo ubiquitination [5]. Here we report that the same impair-
ment of downregulation takes place upon inhibiting the activity
of ‘regular’ (e.g., overexpressed or mutated) oncogenic MET forms
by anti-MET small molecules, although in the current case the
receptor accumulates initially in an inactive state. Importantly,
by envision, in an in vivo systemwhere the concentration gradients
of drugs are common in tumors, our present ﬁnding could possibly
translate into appalling consequences once the inhibitor drops be-
low the inhibitory concentration in some cells within a tumor.
In summary, to our knowledge, this is the ﬁrst report to de-
scribe that targeting of the MET RTK by small molecule inhibitors
leads to its cell surface accumulation by potential interference with
a downregulation-associated mechanism. This phenomenon might
represent an important aspect to be considered following MET
inhibition in clinical setups. It might also be important to further
question as why similar observations have not been so far seen
with other drugable RTKs. For example, EGFR downregulation via
ubiquitination is also mediated through the CBL ubiquitin ligase,
a process in which Y1045 of the EGFR [32] plays a very analogous
role to that of MET Y1003. Nevertheless, comparable ﬁndings to
those reported here following EGFR blocking with erlotinib or gef-
itinib have not been yet described. The molecular mechanisms
underlying such differences may be related to potential variations
in CBL-mediated downregulation of a wt receptor form compared
with its mutated variants, an option that would have yet to be
determined.
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